BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Core Insights - BioAtla, Inc. announced promising data for evalstotug, a novel anti-CTLA-4 antibody, showing prolonged progression-free survival (PFS) of over 10 months in refractory patients [2][3] - The company is on track to complete Phase 1 dose-escalation studies and anticipates initiating a Phase 3 trial for evalstotug in the second half of 2024 [1][2] Group 1: Clinical Data and Efficacy - Evalstotug demonstrated confirmed responses in patients, with a disease control rate of 52% and three patients remaining without progression for over 1 year [4] - In a Phase 1 study, patients treated with 350 mg of evalstotug received a mean of 7.2 doses, indicating good tolerability and no dose reductions [3] - The drug was well-tolerated, with only four patients experiencing Grade 3 treatment-emergent adverse events (TEAEs) and no Grade 4 or 5 TEAEs observed [3] Group 2: Development Plans - The company is currently enrolling patients in Phase 2 studies for first-line melanoma and mutated non-small cell lung cancer (NSCLC) combination cohorts, with plans to transition to a 1 gram flat dose in June [2][3] - A Phase 3 trial for evalstotug in first-line metastatic, unresectable BRAF-mutated melanoma is expected to start in the second half of 2024 following a planned FDA meeting [1][2] Group 3: Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) therapeutics for solid tumors, with a proprietary technology aimed at reducing systemic toxicity while enhancing efficacy [5][6] - The company has extensive patent coverage for its CAB technology, with over 765 active patent matters, indicating a strong intellectual property position [6]